Background/Aim: New fractionation schedules with modern tools are a very rapidly developing area in curative radiotherapy (RT) for early prostate cancer (PC). To apply these techniques in everyday clinical practice, we planned this phase II trial with different fractionation schedules and followed up patients using careful healthrelated quality of life (QoL) questionnaires for three years. Patients and Methods: Seventy-three PC patients with one or two intermediate PC risk factors according to the National Comprehensive Cancer Network criteria were recruited. Forty-two patients were treated with 78/2 Gy (conventional fractionation, CF) or 60/3 Gy (moderately hypofractionation RT, MHF), and 31 patients were treated with 36.25/7.25 Gy (stereotactic body RT, SBRT). Their PSA levels were measured, and QoL data were assessed for genitourinary (GU), gastrointestinal (GI), and sexual well-being between the baseline and three years after treatment. A Rectafix™ (RF) fixation device was used in 30 patients in the CF/MHF group. Results: Three years after radiotherapy (RT), there were no differences between the groups regarding GU, GI, sexual well-being, PSA response, or clinical outcomes. On QoL questionnaires, men in the SBRT group were more satisfied with their QoL at the end of RT. Urinary symptoms (p=0.004) and urinary incontinence were more common in the CF/MHF group (p=0.016) three months after RT. The use of RF reduced GI toxicity, especially urgency (p=0.002), at three years after RT. Conclusion: Modern, short, five-fraction stereotactic radiotherapy as a local curative treatment for PC is well tolerated and safe. Our novel results showing a decrease in GI toxicity using Rectafix™ fixation should be confirmed in future randomized trials.
Prostate cancer has the highest incidence of all cancers inFinland. In 2021, approximately 5,200 new prostate cancers were diagnosed (1). Globally, prostate cancer was the second most common cancer diagnosis in men in 2020 (2). The treatment selection for prostate cancer depends on the patient's cancer risk stratification, which includes Gleason score (ISUP grade), T stage, and prostate specific antigen (PSA) levels (3). According to the European Association of Urology prostate cancer guidelines, management approaches for patients with early prostate cancer include radical prostatectomy, external beam radiation therapy, active surveillance, and brachytherapy (3). Early prostate cancer outcomes are excellent with all treatment options (4-6). In addition to PSA levels, treatment responses after RT could be easily followed with MRI (7). Quality of life (QoL) issues are discussed, and comorbidities are evaluated when the optimal treatment for prostate-confined cancer is selected.The aim of this study was to evaluate an optimal fractionation schedule for modern image-guided external beam radiation therapy in Finnish men with early prostate cancer considering treatment results and patient-reported quality-of-life outcomes (8). The benefits of the rectum immobilization device were also eva...